Top

Optie A:

Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:

Deel de link per e-mail
Link delen

vorige hoofdstuk Founder mutations in hypertrophic cardiomyopath...

volgende hoofdstuk Recurrent and founder mutations in the Netherla...

Tip

Swipe om te navigeren naar een ander hoofdstuk

2014 | OriginalPaper | Hoofdstuk

7. Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy*

eerste hoofdstuk lezen

Auteurs: A. van den Wijngaard, P. Volders, J. P. Van Tintelen, J. D. H. Jongbloed, M. P. van den Berg, R. H. Lekanne Deprez, M. M. A. M. Mannens, N. Hofmann, M. Slegtenhorst, D. Dooijes, M. Michels, Y. Arens, R. Jongbloed, B. J. M. Smeets

Uitgeverij: Bohn Stafleu van Loghum

Gepubliceerd in: Founder mutations in inherited cardiac diseases in the Netherlands

» Toegang tot de volledige tekst krijgen

Samenvatting

Background

About 2-7% of familial cardiomyopathy cases are caused by a mutation in the gene encoding cardiac troponin I (TNNI3). The related clinical phenotype is usually severe with early onset. Here we report on all currently known mutations in the Dutch population and compared these with those described in literature.

Methods

The TNNI3 gene was screened for mutations in all coding exons and flanking intronic sequences in a large cohort of cardiomyopathy patients. All Dutch index cases carrying a TNNI3 mutation that are described in this study underwent extensive cardiological evaluation and were listed by their postal codes.

Results

In 30 families, 14 different mutations were identified. Three TNNI3 mutations were found relatively frequently in both familial and non-familial cases of hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy (RCM). Haplotype analysis showed that p.Arg145Trp and p.Ser166Phe are founder mutations in the Netherlands, while p.Glu209Ala is not. The majority of Dutch TNNI3 mutations were associated with a HCM phenotype. Mean age at diagnosis was 36.5 years. Mutations causing RCM occurred less frequently, but were identified in very young children with a poor prognosis.

Conclusion

In line with previously published data, we found TNNI3 mutations to be rare and associated with early onset and severe clinical presentation.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

Dit product is nog niet beschikbaar met een online abonnement

Meer informatie

Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19(1):104–10. Epub 2007 Oct 4. PubMed

Gomes AV, Potter JD. Molecular and cellular aspects of troponin cardiomyopathies. Ann NY Acad Sci. 2004;1015:214–24. CrossRefPubMed

Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(12):2315–25. CrossRefPubMed

Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16(4):379–82. CrossRefPubMed

Doolan A, Tebo M, Ingles J, et al. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J Mol Cell Cardiol. 2005;38(2):387–93. CrossRefPubMed

Kaski JP, Syrris P, Burch M, et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart. 2008;94(11):1478–84. CrossRefPubMed

Carballo S, Robinson P, Otway R, et al. Identification and functional characterization of cardiac troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ Res. 2009;105(4):375–82. CrossRefPubMed

Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol. 2007;49(25):2419–26. Epub 2007 Jun 11. CrossRefPubMed

Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2008;369(1):82–7. CrossRefPubMed

10.

Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR. Phosphorylation-dependent conformational transition of the cardiac specific N-extension of troponin I in cardiac troponin. J Mol Biol. 2007;373(3):706–22. CrossRefPubMed

11.

Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003;108(4):445–51. CrossRefPubMed

12.

Ward DG, Ashton PR, Trayer HR, Trayer IP. Additional PKA phosphorylation sites in human cardiac troponin I. Eur J Biochem. 2001;268(1):179–85. CrossRefPubMed

13.

Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336(4):267–76. CrossRefPubMed

14.

Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest. 2003;111(2):209–16. CrossRefPubMedPubMedCentral

15.

Fokstuen S, Lyle R, Munoz A, et al. A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat. 2008;29(6):879–85. CrossRefPubMed

16.

Andersen PS, Havndrup O, Hougs L, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat. 2009;30(3):363–70. CrossRefPubMed

17.

Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart. 2005;91(8):1036–40. CrossRefPubMedPubMedCentral

18.

Tripet B, Van Eyk JE, Hodges RS. Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+−dependent regulation of muscle contraction. J Mol Biol. 1997;271(5):728–50. CrossRefPubMed

19.

Rarick HM, Tu XH, Solaro RJ, Martin AF. The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat myofibrils. J Biol Chem. 1997;272(43):26887–92. CrossRefPubMed

Titel

Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy*

Boek

Founder mutations in inherited cardiac diseases in the Netherlands

Print ISBN: 978-90-368-0704-3

Elektronisch ISBN: 978-90-368-0705-0

https://doi.org/10.1007/978-90-368-0705-0

DOI

https://doi.org/10.1007/978-90-368-0705-0_7

Auteurs:

A. van den Wijngaard
P. Volders
J. P. Van Tintelen
J. D. H. Jongbloed
M. P. van den Berg
R. H. Lekanne Deprez
M. M. A. M. Mannens
N. Hofmann
M. Slegtenhorst
D. Dooijes
M. Michels
Y. Arens
R. Jongbloed
B. J. M. Smeets

Uitgeverij

Bohn Stafleu van Loghum

Volgnummer

Hoofdstuknummer